Celsis sold its In-Vitro Technologies division to a trade buyer. The division, which is non-core to Celsis, employs proprietary hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical industry.
Following this divestment, and the sale of the Analytical Services division in December 2012, Celsis is now concentrated on its core business of Rapid Detection. Harwood Private Equity acquired the company in 2009 in a public-to-private transaction.